209 related articles for article (PubMed ID: 24455664)
1. Clinical challenges: Myeloma and concomitant type 2 diabetes.
Ali MA; Ahmed YA; Ibrahim A
South Asian J Cancer; 2013 Oct; 2(4):290-5. PubMed ID: 24455664
[TBL] [Abstract][Full Text] [Related]
2. Clinical challenges: myeloma and concomitant type 2 diabetes.
Ahmed YA; Eltayeb A
Int J Hematol Oncol Stem Cell Res; 2013; 7(1):34-41. PubMed ID: 24505516
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma and diabetes.
Issa ZA; Zantout MS; Azar ST
ISRN Endocrinol; 2011; 2011():815013. PubMed ID: 22363889
[TBL] [Abstract][Full Text] [Related]
4. Concomitant multiple myeloma spectrum diagnosis in a central retinal vein occlusion: a case report and review.
Borgman CJ
Clin Exp Optom; 2016 Jul; 99(4):309-12. PubMed ID: 27079282
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan hydrogels delivering BMP-6 for local targeting of malignant plasma cells and osteogenic differentiation of mesenchymal stromal cells.
Grab AL; Seckinger A; Horn P; Hose D; Cavalcanti-Adam EA
Acta Biomater; 2019 Sep; 96():258-270. PubMed ID: 31302300
[TBL] [Abstract][Full Text] [Related]
6. Enrichment-Free Single-Cell Detection and Morphogenomic Profiling of Myeloma Patient Samples to Delineate Circulating Rare Plasma Cell Clones.
Ndacayisaba LJ; Rappard KE; Shishido SN; Ruiz Velasco C; Matsumoto N; Navarez R; Tang G; Lin P; Setayesh SM; Naghdloo A; Hsu CJ; Maney C; Symer D; Bethel K; Kelly K; Merchant A; Orlowski R; Hicks J; Mason J; Manasanch EE; Kuhn P
Curr Oncol; 2022 Apr; 29(5):2954-2972. PubMed ID: 35621632
[TBL] [Abstract][Full Text] [Related]
7. The Role of Marrow Microenvironment in the Growth and Development of Malignant Plasma Cells in Multiple Myeloma.
Giannakoulas N; Ntanasis-Stathopoulos I; Terpos E
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923357
[TBL] [Abstract][Full Text] [Related]
8. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment.
Hewett DR; Vandyke K; Lawrence DM; Friend N; Noll JE; Geoghegan JM; Croucher PI; Zannettino ACW
Neoplasia; 2017 Dec; 19(12):972-981. PubMed ID: 29091798
[TBL] [Abstract][Full Text] [Related]
9. Prevalence, mutational spectrum and clinical implications of clonal hematopoiesis of indeterminate potential in plasma cell dyscrasias.
Testa S; Kumar J; Goodell AJ; Zehnder JL; Alexander KM; Sidana S; Arai S; Witteles RM; Liedtke M
Semin Oncol; 2022 Dec; 49(6):465-475. PubMed ID: 36503855
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and clinical considerations in concomitant bone marrow involvement by plasma cell myeloma and chronic lymphocytic leukemia/monoclonal B-cell lymphocytosis: a series of 15 cases and review of literature.
Alley CL; Wang E; Dunphy CH; Gong JZ; Lu CM; Boswell EL; Burchette J; Lagoo AS
Arch Pathol Lab Med; 2013 Apr; 137(4):503-17. PubMed ID: 23544940
[TBL] [Abstract][Full Text] [Related]
11. Reduced Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma in Type 2 Diabetes Mellitus: Will Metformin Never Stop Its Pleasant Surprises?
Papachristou S; Popovic DS; Papanas N
Adv Ther; 2022 Jun; 39(6):2283-2286. PubMed ID: 35344184
[TBL] [Abstract][Full Text] [Related]
12. Multiple Myeloma: Challenges Encountered and Future Options for Better Treatment.
Das S; Juliana N; Yazit NAA; Azmani S; Abu IF
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163567
[TBL] [Abstract][Full Text] [Related]
13. Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells.
Noll JE; Williams SA; Tong CM; Wang H; Quach JM; Purton LE; Pilkington K; To LB; Evdokiou A; Gronthos S; Zannettino AC
Haematologica; 2014 Jan; 99(1):163-71. PubMed ID: 23935020
[TBL] [Abstract][Full Text] [Related]
14. Multiple Myeloma (Part 1) - Update on Epidemiology, Diagnostic Criteria, Systemic Treatment and Prognosis.
Guedes A; Becker RG; Teixeira LEM
Rev Bras Ortop (Sao Paulo); 2023 Jun; 58(3):361-367. PubMed ID: 37396092
[TBL] [Abstract][Full Text] [Related]
15. Circulating MicroRNAs in Multiple Myeloma: a Literature Review.
Tiruneh T; Melku M
Clin Lab; 2020 Dec; 66(12):. PubMed ID: 33337835
[TBL] [Abstract][Full Text] [Related]
16. Report of the committee on the classification and diagnostic criteria of diabetes mellitus.
; Seino Y; Nanjo K; Tajima N; Kadowaki T; Kashiwagi A; Araki E; Ito C; Inagaki N; Iwamoto Y; Kasuga M; Hanafusa T; Haneda M; Ueki K
J Diabetes Investig; 2010 Oct; 1(5):212-28. PubMed ID: 24843435
[TBL] [Abstract][Full Text] [Related]
17. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus.
Kuzuya T; Nakagawa S; Satoh J; Kanazawa Y; Iwamoto Y; Kobayashi M; Nanjo K; Sasaki A; Seino Y; Ito C; Shima K; Nonaka K; Kadowaki T;
Diabetes Res Clin Pract; 2002 Jan; 55(1):65-85. PubMed ID: 11755481
[TBL] [Abstract][Full Text] [Related]
18. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.
Tian M; Liu Z; Han M; Liu H; Xiang C; Mi F; Deng L; Meng N; Fu R
Cytometry B Clin Cytom; 2022 Jan; 102(1):44-49. PubMed ID: 34057806
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
20. Game of Bones: How Myeloma Manipulates Its Microenvironment.
Moser-Katz T; Joseph NS; Dhodapkar MV; Lee KP; Boise LH
Front Oncol; 2020; 10():625199. PubMed ID: 33634031
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
